| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5602133 | PFIZER PHARMS | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
Sep, 2013
(10 years ago) | |
| US6046202 | PFIZER PHARMS | Use of thiazolidinedione derivatives in the treatment of insulin resistance |
Sep, 2013
(10 years ago) | |
| US5859037 | PFIZER PHARMS | Sulfonylurea-glitazone combinations for diabetes |
Nov, 2017
(6 years ago) | |
| US6011049 | PFIZER PHARMS | Combinations for diabetes |
Nov, 2017
(6 years ago) | |
Rezulin is owned by Pfizer Pharms.
Rezulin contains Troglitazone.
Rezulin has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Rezulin are:
- US5602133
- US6046202
- US5859037
- US6011049
Rezulin was authorised for market use on 29 January, 1997.
Rezulin is available in tablet;oral dosage forms.
Rezulin can be used as use of troglitazone in combination with sulfonylureas in the treatment of type ii diabetes, administration to a host suffering from gestational diabetes, use of troglitazone in combination with sulfonylureas and biguanides in the treatment of type ii diabetes, method of using troglitazone to treat patients having insulin resistance.
The generics of Rezulin are possible to be released after 13 November, 2017.
Drugs and Companies using TROGLITAZONE ingredient
Market Authorisation Date: 29 January, 1997
Treatment: Administration to a host suffering from gestational diabetes; Method of using troglitazone to treat patients having insulin resistance; Use of troglitazone in combination with sulfonylureas in the tre...
Dosage: TABLET;ORAL
REZULIN family patents
